Estetrol Combined to Progestogen for Menopause or Contraception Indication Is Neutral on Breast Cancer

Estetrol Combined to Progestogen for Menopause or Contraception Indication Is Neutral on Breast Cancer

Given the unequivocal benefits of menopause hormone therapies (MHT) and combined oral contraceptives (COC), there is a clinical need for new formulations devoid of any risk of breast cancer promotion. Accumulating data from preclinical and clinical studies support that estetrol (E4) is a promising n...

Full description

Bibliographic Details
Main Authors: Anne Gallez, Silvia Blacher, Erik Maquoi, Erika Konradowski, Marc Joiret, Irina Primac, Céline Gérard, Mélanie Taziaux, René Houtman, Liesbet Geris, Françoise Lenfant, Elisabetta Marangoni, Nor Eddine Sounni, Jean-Michel Foidart, Agnès Noël, Christel Péqueux
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
estetrol
estrogen receptor alpha
progesterone
drospirenone
breast cancer
menopause hormone therapy
Online Access:https://www.mdpi.com/2072-6694/13/10/2486

Similar Items

Similar Items